Cargando…

Evaluation of nimotuzumab Fab(2) as an optical imaging agent in EGFR positive cancers

Molecular-targeted imaging probes can be used with a variety of imaging modalities to detect diseased tissues and guide their removal. EGFR is a useful biomarker for a variety of cancers, because it is expressed at high levels relative to normal tissues. Previously, we showed the anti-EGFR antibody...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bernhard, Wendy, Barreto, Kris, Toledo, Darien, El-Sayed, Ayman, Jett, Kimberly A., Casaco, Angel, Fonge, Humphrey, Geyer, C. Ronald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10328982/ https://www.ncbi.nlm.nih.gov/pubmed/37419997 http://dx.doi.org/10.1038/s41598-023-37873-9

Ejemplares similares

Near infrared fluorescence imaging of EGFR expression in vivo using IRDye800CW-nimotuzumab
por: Bernhard, Wendy, et al.
Publicado: (2017)

Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety
por: Bernhard, Wendy, et al.
Publicado: (2021)

Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograft
por: Hartimath, Siddesh V., et al.
Publicado: (2019)

(89)Zr-nimotuzumab for immunoPET imaging of epidermal growth factor receptor I
por: Chekol, Rufael, et al.
Publicado: (2018)

Near infrared imaging of epidermal growth factor receptor positive xenografts in mice with domain I/II specific antibody fragments
por: Bernhard, Wendy, et al.
Publicado: (2019)

Nimotuzumab Site-Specifically Labeled with (89)Zr and (225)Ac Using SpyTag/SpyCatcher for PET Imaging and Alpha Particle Radioimmunotherapy of Epidermal Growth Factor Receptor Positive Cancers
por: Solomon, Viswas Raja, et al.
Publicado: (2020)

Evaluation of antibody fragment properties for near-infrared fluorescence imaging of HER3-positive cancer xenografts
por: El-Sayed, Ayman, et al.
Publicado: (2018)

(89)Zr-Labeled Domain II-Specific scFv-Fc ImmunoPET Probe for Imaging Epidermal Growth Factor Receptor In Vivo
por: Alizadeh, Elahe, et al.
Publicado: (2021)

Development and preclinical evaluation of cixutumumab drug conjugates in a model of insulin growth factor receptor I (IGF-1R) positive cancer
por: Solomon, Viswas Raja, et al.
Publicado: (2020)

A novel synthetic trivalent single chain variable fragment (tri-scFv) construction platform based on the SpyTag/SpyCatcher protein ligase system
por: Alam, Md. Kausar, et al.
Publicado: (2018)

Imaging Immune Cells Using Fc Domain Probes in Mouse Cancer Xenograft Models
por: Bernhard, Wendy, et al.
Publicado: (2022)

Nimotuzumab, an Anti-EGFR Monoclonal Antibody, in the Treatment of Nasopharyngeal Carcinoma
por: Liang, Renba, et al.
Publicado: (2021)

Upregulation of HLA Class I Expression on Tumor Cells by the Anti-EGFR Antibody Nimotuzumab
por: Garrido, Greta, et al.
Publicado: (2017)

EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab's Clinical Effects
por: Perez, Rolando, et al.
Publicado: (2011)

Blocking EGFR with nimotuzumab: a novel strategy for COVID-19 treatment
por: Londres, Henrry Diaz, et al.
Publicado: (2022)

An EGCG Derivative in Combination with Nimotuzumab for the Treatment of Wild-Type EGFR NSCLC
por: Huang, Yanping, et al.
Publicado: (2023)

Next-generation sequencing-guided identification and reconstruction of antibody CDR combinations from phage selection outputs
por: Barreto, Kris, et al.
Publicado: (2019)

Heterogeneity of resistant mechanisms in an EGFR-TKI relapsed patient with EGFR amplification and response to nimotuzumab: A case report
por: Li, Yan, et al.
Publicado: (2022)

Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma
por: Ronellenfitsch, Michael W., et al.
Publicado: (2018)

MicroRNA-566 activates EGFR signaling and its inhibition sensitizes glioblastoma cells to nimotuzumab
por: Zhang, Kai-Liang, et al.
Publicado: (2014)

Nimotuzumab enhances temozolomide‐induced growth suppression of glioma cells expressing mutant EGFR in vivo
por: Nitta, Yusuke, et al.
Publicado: (2016)

Production and Semi-Automated Processing of (89)Zr Using a Commercially Available TRASIS MiniAiO Module
por: Gaja, Vijay, et al.
Publicado: (2020)

Nimotuzumab as a radiosensitizing agent in the treatment of high grade glioma: challenges and opportunities
por: Diaz-Miqueli, Arlhee, et al.
Publicado: (2013)

Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3
por: Zhao, Lei, et al.
Publicado: (2012)

Nimotuzumab for COVID-19: case series
por: Abdo Cuza, Anselmo A, et al.
Publicado: (2021)

Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status
por: Chong, Dawn Q, et al.
Publicado: (2015)

Development of an Epidermal Growth Factor Derivative with EGFR Blocking Activity
por: Panosa, Clara, et al.
Publicado: (2013)

Synthetic antigen-binding fragments (Fabs) against S. mutans and S. sobrinus inhibit caries formation
por: Alam, Md. Kausar, et al.
Publicado: (2018)

Single chain Fab (scFab) fragment
por: Hust, Michael, et al.
Publicado: (2007)

Radiotherapy Plus Temozolomide With or Without Nimotuzumab Against the Newly Diagnosed EGFR-Positive Glioblastoma: A Retrospective Cohort Study
por: She, Lei, et al.
Publicado: (2022)

Profile of nimotuzumab in the treatment of high-grade glioma
por: Yang, Qun-ying, et al.
Publicado: (2015)

Nimotuzumab for Patients With Inoperable Cancer of the Head and Neck
por: Crombet Ramos, Tania, et al.
Publicado: (2020)

Nimotuzumab abrogates acquired radioresistance of KYSE-150R esophageal cancer cells by inhibiting EGFR signaling and cellular DNA repair
por: Liu, Hai, et al.
Publicado: (2015)

Author Correction: Synthetic antigen-binding fragments (Fabs) against S. mutans and S. sobrinus inhibit caries formation
por: Alam, Md. Kausar, et al.
Publicado: (2020)

Nimotuzumab in the Treatment of Inoperable Esophageal Tumors of Epithelial Origin
por: González Fernández, Sandra, et al.
Publicado: (2022)

Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients
por: Mazorra, Zaima, et al.
Publicado: (2017)

Simultaneous Imaging and Therapy Using Epitope-Specific Anti-Epidermal Growth Factor Receptor (EGFR) Antibody Conjugates
por: Tikum, Anjong Florence, et al.
Publicado: (2022)

Production of single chain Fab (scFab) fragments in Bacillus megaterium
por: Jordan, Eva, et al.
Publicado: (2007)

Bioinformatic Analysis of Hepatocellular Carcinoma Cell Lines to the Efficacy of Nimotuzumab
por: Wang, Yu, et al.
Publicado: (2021)

Nimotuzumab Concurrent with Gemcitabine as First-Line Treatment of Locally Advanced or Metastatic Pancreatic Adenocarcinoma
por: Sánchez, Yamirka, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uv6t06ht2gma89903t7dvkiatp